Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.38 |
| ▸ | BTK | Q06187 | 5/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 6/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8990365 | 0.89 | EIF2AK4 (0.36) | EIF2AK4WNT3A | |
| SCHEMBL8990167 | 0.87 | KMT2A (0.36) | EIF2AK4 | |
| SCHEMBL8988167 | 0.84 | EIF2AK4 (0.34) | EIF2AK4WNT3A | |
| SCHEMBL8990162 | 0.84 | TSHR (0.38) | EIF2AK4WNT3A | |
| SCHEMBL13933293 | 0.84 | EIF2AK4 (0.39) | EIF2AK4WNT3A | |
| SCHEMBL8987971 | 0.84 | EIF2AK4 (0.40) | EIF2AK4WNT3A | |
| SCHEMBL8985979 | 0.83 | EIF2AK4 (0.38) | EIF2AK4 | |
| SCHEMBL8987864 | 0.81 | EIF2AK4 (0.38) | EIF2AK4 | |
| SCHEMBL12341821 | 0.81 | EIF2AK4 (0.37) | EIF2AK4 | |
| SCHEMBL8940851 | 0.78 | BTK (0.48) | JAK3BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | JAK3 1/4885BTK 29/4885EIF2AK4 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.